secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001628280-25-038547
Event type: earnings
Sentiment:  positive
Materiality: 0.77
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab Q2 revenue grows 9% YoY to $110M; operating loss improves 28%; targets Q4 profitability
--------------------------------------------------------------------------------

- Product revenue $109.1M (+9% YoY); VYVGART sales $26.5M (+46% QoQ); ZEJULA $41.0M (down from $45M YoY).
- GAAP operating loss $54.9M (improved 28% YoY); adjusted operating loss $34.2M (improved 37% YoY).
- Net loss $40.7M vs $80.3M YoY; cash $832.3M as of June 30, 2025.
- Reaffirms FY2025 revenue guidance $560M-$590M; on track for adjusted profitability in Q4 2025.
- Pipeline: ZL-1310 ORR 79% at 1.6mg/kg in 2L ES-SCLC; bemarituzumab Phase 3 met OS endpoint; China submission H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000162828025038547/0001628280-25-038547-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000162828025038547/zlab-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-038547

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer